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Abstract
Background: Major depression is a common mental disorder that substantially impairs quality of life and has high
societal costs. Although psychotherapies have proven to be effective antidepressant treatments, initial response
rates are insufficient and the risk of relapse and recurrence is high. Improvement of treatments is badly needed.
Studying the mechanisms of change in treatment might be a good investment for improving everyday mental
health care. However, the mechanisms underlying therapeutic change remain largely unknown. The objective of
the current study is to assess both the effectiveness of two commonly used psychotherapies for depression in
terms of reduction of symptoms and prevention of relapse on short and long term, as well as identifying
underlying mechanisms of change.
Methods: In a randomised trial we will compare (a) Cognitive Therapy (CT) with (b) Interpersonal therapy (IPT), and
(c) an 8-week waiting list condition followed by treatment of choice. One hundred eighty depressed patients (aged
18-65) will be recruited in a mental health care centre in Maastricht (the Netherlands). Eligible patients will be
randomly allocated to one of the three intervention groups. The primary outcome measure of the clinical
evaluation is depression severity measured by the Beck Depression Intenvory-II (BDI-II). Other outcomes include
process variables such as dysfunctional beliefs, negative attributions, and interpersonal problems. All self-report
outcome assessments will take place on the internet at baseline, three, seven, eight, nine, ten, eleven, twelve and
twenty-four months. At 24 months a retrospective telephone interview will be administered. Furthermore, a
rudimentary analysis of the cost-effectiveness will be embedded. The study has been ethically approved and
registered.
Discussion: By comparing CT and IPT head-to-head and by investigating multiple potential mediators and
outcomes at multiple time points during and after therapy, we hope to provide new insights in the effectiveness
and mechanisms of change of CT and IPT for depression, and contribute to the improvement of mental health
care for adults suffering from depression.
Trial registration: The study has been registered at the Netherlands Trial Register, part of the Dutch Cochrane
Centre (ISRCTN67561918)
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With a lifetime prevalence of 17%, depression is a major
health problem with serious clinical and social conse-
quences. It is expected that depression will be the lead-
ing global cause of years of health lost due to disease in
2030 [1]. With initial response rates up to 60%, and the
majority of patients regaining their normal level of func-
tioning within three years, certain psychotherapies and
antidepressant medication have proven efficacy in treat-
ing acute Major Depressive Disorder (MDD) [2,3]. This
might sound promising, but at least 40% of depressed
patients do not respond to initial treatment at all.
Furthermore, depression has an unfavourable prognosis;
even when treated effectively in the acute phase, recov-
ery is often incomplete, which increases the chance of
relapse and recurrence up to 87% over 15 years [4-7].
With this in mind, the challenge in contemporary
depression research is to improve treatments to increase
acute response rates and prevent relapse and recurrence in
the long term. Many researchers agree that knowledge of
underlying mechanisms that can explain therapeutic
change is a key to improving treatment [8,9]. Knowing
how a therapy works would allow honing its components
to make it more efficient and (cost-)effective [10]. The cur-
rent study will focus on the effectiveness, prevention of
relapse and recurrence and mechanisms of change of two
commonly used types of psychotherapy for depression:
Cognitive Therapy (CT) [11] and Interpersonal Therapy
(IPT) [12]. A rudimentary analysis of the cost-effectiveness
from a societal perspective will be embedded.
Effectiveness
Of the psychotherapeutic interventions for depression,
CT and IPT might be the two best studied and empiri-
cally validated [13-15]. They come from different theo-
retical backgrounds: CT derives from Beck’sc o g n i t i v e
theory and explains depression as a result of maladap-
tive information-processing, whereas IPT links depres-
sive episodes to distressing life events and insufficient
social support [12,16]. Nonetheless, both therapies have
proven to be well-standardized, efficacious treatments
for acute treatment of MDD [3,12,17-23]. There is no
consensus yet about whether the effect of one therapy
outperforms the other. Many studies have investigated
the effects of CT and IPT separately, but only 2 large
studies have compared them head-to-head [24-26].
However, doubts have arisen about the validity of one of
these studies because analysis of treatment adherence
showed no contrast between the two intervention
groups [24,27]. Thus, the current view is based on only
one methodologically well-designed study. Therefore,
there is a need for renewed head-to-head comparisons
of both therapies.
Relapse Prevention
In addition to the fact that CT and IPT have shown to
be efficacious acute treatments of MDD, they may also
reduce the risk of relapse (episode of MDD after remis-
sion) and recurrence (episode of MDD after recovery) in
the long term. The effects and evidence differ for the
two therapies. Research has shown that CT has an
enduring effect that extends beyond the end of therapy
[12,28-33], thereby reducing the chances of relapse and
recurrence. The evidence for this is strong and consis-
tent [31,34,35]. However, the long term effect of IPT
has not been tested extensively yet. Up until now it has
only been tested as a maintenance treatment [36,37],
and the question remains whether IPT also has an
enduring effect that remains after therapy is finished.
This question should be further explored. Insight in the
long term effects of IPT furthermore creates the oppor-
tunity to compare CT and IPT to assess whether one
therapy is superior to the other in preventing relapse
and recurrence in the long term [15].
Mechanisms of Change
As noted above, insight into mechanisms of change
might contribute to the process of therapy improvement.
However, the mechanisms that cause therapeutic change
are still largely unknown. Despite several research
attempts to identify the mechanisms of change in psy-
chotherapy, no study has identified a model that explains
change in CT or IPT completely [38,39]. Mechanism
research has to cope with several methodological and
theoretical difficulties [40,41]. Theoretical difficulties
arise because there are conflicting hypotheses on the
mechanisms and there is no consensus about the most
important causes of change [38,42]. For example, it is
unclear whether therapeutic change can be better
explained by change in treatment specific factors [42-45]
or non-specific (common) factors [46-48]. Specific factors
are elements marked as the active causes of change in the
theory of the therapy, such as change in cognitions in CT
and optimization of interpersonal functioning in IPT.
Non-specific factors refer to elements in a therapy that
contribute to improvement, but that are common to all
psychotherapies, such as expectancy and therapeutic alli-
ance [49]. Furthermore, it is not exactly known whether
changes achieved in therapy are best reflected by explicit
or by implicit measures of psychopathology. Explicit
measures depend on introspection, and a disadvantage is
that it is known that people do not have access to all of
the mechanisms that underlie their behaviour [50]. An
implicit measure is defined by De Houwer, Teige-Moci-
gemba, Spruyt, and Moors (2009) as “a measurement
outcome that is causally produced by the to-be-measured
attribute in the absence of certain goals, awareness,
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350) [51]. To the extent that implicit measures reflect
uncontrollable, unaware, fast mechanisms, they could
provide information that augments that from explicit
measures [52].
Furthermore, methodological difficulties arise because
many study designs do not meet the criteria for reputa-
ble mechanisms research [40,41]. Theories often explain
change in terms of causal processes. However, in many
studies it is difficult to identify temporal relationships in
order to investigate these causal pathways because of
the absence of an appropriate time line and assessment
on multiple time points [40,41]. It is clear that there is a
need for renewed, methodologically well-considered
mechanism research.
The question remains what is necessary for proper
mechanism research. According to Kazdin (2007), a first
step into investigating mechanisms of change is studying
mediating variables [40]. A mediator explains why and
in what way a treatment has an effect on the outcome,
and plays a crucial role in the development of causal
pathways. In identifying mediators, Kazdin has built
upon the MacArthur guidelines of Kraemer et al. (2001)
[53] which are based on the more traditional guidelines
for statistical mediation formulated by Baron and Kenny
(1986) [54]. In addition to statistical mediation and asso-
ciation, Kazdin emphasizes the importance of the tem-
poral relationship, and consistency and specificity of the
mediator. The importance of the aspect of temporality
is also emphasized by Murphy et al (2009) [55]. Taking
this into account, the current study will investigate
potential mediators of CT for depression and test their
specificity in comparison to IPT, and vice versa, by mea-
suring multiple potential mediators and outcomes at
multiple time points during and after therapy. This
method enables us to investigate temporal relationships
between changes in potential mediators and symptom
reduction and to assess whether change in a mediator
precedes, follows from, or goes together with changes in
depression. In addition, this method can show us
whether change in one mediator precedes change in
another mediator.
Main research questions and Hypotheses
The following main research questions were formulated:
￿ Are CT and IPT effective interventions in treating
the acute phase of MDD and is one therapy superior
to the other?
￿ What are the underlying psychological mechanisms
of change in CT and IPT and are these mechanisms
therapy-specific?
￿ Are CT and IPT effective in preventing relapse or
recurrence of MDD in the long-term? Is one therapy
superior to the other, and if so, how can these pre-
ventive effects be explained?
In line with previous research, it is hypothesized that the
amount of change in depressive symptoms after therapy
will be similar in both the CT and the IPT group, indicat-
ing that both treatments are just as effective in treating
depression in the acute phase [14,24,56,57]. Because both
therapies originally stem from different theoretical back-
grounds, we expect that both treatments target depression
through different key processes. It is expected that changes
in cognitive schemas, attitudes, and cognitions are the
most significant contributors to symptom change in CT,
whereas in IPT it is assumed that improvement of inter-
personal functioning will lead to a reduction of symptoms
[12,16]. With regard to the mechanisms of change, many
hypotheses are possible, especially when it comes to the
order of change and causal pathways that lead to recovery.
Following the theories one would expect that change in
cognitions (CT) and interpersonal functioning (IPT) pre-
cede symptom change. Furthermore, we expect that it is
the direct comparison of explicit versus implicit measures
that will elicit new insights into the underlying mechan-
isms of change. To the extent that implicit measures
reflect uncontrollable, unaware and fast mechanisms, they
can provide useful additional information as compared to
explicit measures. As to the prevention of relapse, we
hypothesize that both CT and IPT may reduce the risk of
relapse and recurrence in the long term. However, we
expect CT to prevent relapse to a greater extent, because
it has shown to have an enduring effect that extends
beyond the end of therapy, while IPT so far only seems to
be effective in treating depression as long as the treatment
is continued [58].
Methods
Design of the study
We will conduct a randomised controlled trial (RCT) in
which participants will be allocated to one of three con-
ditions: (a) CT (N = 75), (b) IPT (N = 75), (c) or a wait-
ing list condition followed by treatment of choice (N =
30). Participants allocated to the waiting list condition
start their treatment after an 8-week waiting period. To
compensate for the waiting, they may choose their pre-
ferred treatment (CT or IPT). The anticipated flow of
subject enrolment is graphically shown in Figure 1. The
Medical Ethics Committee of Maastricht University
approved the study protocol. The study is registered at
the Netherlands Trial Register, part of the Dutch
Cochrane Centre (ISRCTN67561918).
Participants
T h ep o p u l a t i o nw ea i mt oi n v e s t i g a t ec o n s i s t so f1 8 0
depressed adults. Patients will be eligible to participate if
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years old; the presence of a depressive episode as indi-
cated by a diagnosis on the Structural Clinical Interview
f o rD S M - I VA x i sId i s o r d e r s( S C I D - I )[ 5 9 ] ;i n t e r n e t
access and an e-mail address; sufficient knowledge of
the Dutch language; no chronic depression (>5 years);
no current use of antidepressant mediation; no severe
psychiatric co-morbidity, drugs- and alcohol abuse/
dependence and oligophrenia.
Sample size
To calculate the sample size of the CT and IPT group,
we combined rudimentary findings from previous ran-
domised trials, which resulted in a mean relapse/recur-
rence rate of 33% after two years of follow-up,
compared to 67% following antidepressant medication
and/or clinical management [28,29,31-33]. Based on
t h e s er e s u l t s ,w ea s s u m ead i f f e r e n c eo f2 0 %i nr e l a p s e
between CT and IPT. Using survival analysis (two-sided,
a = 0.05, power = 80%), we calculated that 75 patients
per treatment condition would suffice to detect this sta-
tistically significant difference rate in relapse/recurrence
between the two conditions in the long term.
A waiting list condition is included to investigate
whether the effects of CT and IPT exceed the outcome
in patients who do not receive treatment, a finding that
has been demonstrated in numerous previous studies
[60-63]. A power calculation showed that 30 participants
in the waiting list condition will be sufficient to detect a
statistically significant difference between the two active
conditions combined (CT and IPT) and the waiting list
after eight weeks.
Recruitment
Participants will be recruited during regular intakes at
our clinical site, the Academic Community Mental
Health Centre (RIAGG) Maastricht. The SCID-I will be
administered to assess current and lifetime episodes of
Axis I disorders [59]. Patients meeting the inclusion cri-
teria will be approached for participation. If they agree
to participate, the SCID for Axis II disorders (SCID-II)
will be administered as well [64]. After inclusion, the
participants’ GP will be informed about his or her parti-
cipation in the study. Participants who do not meet the
inclusion criteria will be offered suitable alternative
treatment options.
Randomisation and procedure
Eligible participants will be contacted by telephone for a
baseline visit at the university. Preceding this initial visit
to the research centre, participants will receive an
appointment letter, including study information. This
will allow them to consider their study participation
well before they agree to participate (approximately one
week). Furthermore, to decrease the burden of the first
assessment, participants will be asked to already fill out
a substantial part of the baseline questionnaires at
home. Randomisation will take place after informed
consent is obtained and the second part of the baseline
questionnaires are filled out. In our design we prestrati-
fied groups by first (1 episode) and recurrent (> 1 epi-
sodes) depression. The researcher will press the ‘assign’
button on the computer screen, after which the database
randomly allocates the participant to one of the treat-
ment conditions (CT or IPT), or to the waiting list con-
dition by using block randomisation. This waiting list
condition is included because it has been frequently
argued in psychotherapy research that the effect in
treatment studies cannot be attributed to the interven-
tion(s) that are studied, unless a placebo or no-treat-
m e n tg r o u pi si n c l u d e d[ 6 5 ] .W i t hr e g a r dt ot h en a t u r e
of the treatments, blinding of the participants and
researchers is not possible.
I nr e p o r t i n gt h ef o l l o w - u pp e r i o do ft h eC Ta n dI P T
condition in this study, we distinguish three phases; (a)
t h eT r e a t m e n tp h a s e( b a s e l i n et o7m o n t h s ) ;t h ep e r i o d
when therapy will be delivered; (b) The Trial follow-up
phase (month 8-12) in which depression severity will be
measured monthly; and (c) The Long-term follow-up
Figure 1 Flow of the Participants.
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spective assessment. All questionnaires will be adminis-
tered on a computer. Pre- and post treatment assessment
(baseline and 7 months) will take place at the University.
All other follow-up self-report assessments will take
p l a c ea th o m ev i at h ei n t e r n e ta tt h r e e ,e i g h t ,n i n e ,t e n ,
eleven, twelve and twenty-four months after inclusion.
Although the baseline assessment is the same, the fol-
low-up period of the waiting list condition is somewhat
different as compared to the CT and IPT condition (see
Figure 1). Participants in this condition will be measured
less often, and at different points in time. The treatment
phase of the participants in this condition does not start
immediately after baseline, but after an 8-week waiting
list period. To be able to investigate the effect of this
waiting period, and to mark the starting point of the
treatment phase, a second identical baseline assessment
will take place two months after the initial baseline
assessment. As a consequence, the post-treatment
assessment in this condition will take place after nine
months (instead of after seven months in the CT and
IPT condition). Furthermore, patients in this condition
will only have two more assessment after their post-
treatment measure. This will take place at 14 and 26
months, and is identical to the 12 and 24 months
assessment of the CT and IPT condition. To summarize,
patients in the waiting list condition will have the same
baseline assessment as compared to participants in the
CT and IPT condition. However, they will have a second
baseline assessment at two months follow-up, and their
9, 14, and 26 month follow-up assessments will parallel
respectively the 7, 12, and 24 months assessments of the
CT and IPT group (see table 1).
In all conditions a BDI-II will be filled out before each
session during the treatment phase. After the two-year
follow-up period, a modified version of the semi-struc-
tured Longitudinal Interval Follow-Up Evaluation (LIFE)
[66] will be administered to retrospectively map out the
course of depressive symptoms. To optimize the adher-
ence of self-report assessments, participants will receive
an email foregoing each assessment point. If one does
not complete the questionnaires within one week, an
email-reminder will be sent. If the participant still fails
to fill out the questionnaires, a phone call will be made.
Interventions
The interventions will be offered at the Academic
RIAGG Maastricht. At this site, CT and IPT are already
delivered as treatment as usual. Interventions are written
out in a treatment manual, and both treatments will con-
tain 12 to 20 sessions of 45 minutes, depending on the
individual progress of patients. Interventions will be
delivered by qualified therapists, who were trained by
Steven Hollon (CT) and John Markowitz (IPT), experts
in the field of depression treatment. To prevent contami-
nation of treatment conditions, participating therapists
will deliver either CT or IPT. Therapists will consult
each other on current cases in biweekly consultation
meetings. The CT protocol is based on the manual by
Beck (1979) and is modified for the current study with a
special focus on relapse prevention. IPT is based on the
manual of Klerman, Weissman, Rounsaville, and Chevron
Table 1 Overview of instruments per time point in the CT
and IPT group*
Instrument 0** 3 7 8-11 12 24
Clinical Outcome measures
Beck Depression Inventory II ￿￿ ￿ ￿ ￿ ￿
Quick Inventory of Depressive
symptoms
￿￿
Brief Symptom Inventory ￿￿ ￿ ￿
Diagnostic Interview for Depression ￿￿ ￿ ￿ ￿
Beck Hopelessness Scale ￿￿
Longitudinal Interval Follow-up
Evaluation
￿
Process variables
Attributional Style questionnaire ￿￿ ￿ ￿
Dysfunctional Attitude Scale ￿￿ ￿ ￿
Inventory of Interpersonal Problems ￿￿ ￿ ￿ ￿
Leiden Index of Depression Severity ￿￿ ￿
Ruminative Response Scale NL ￿￿ ￿
Self-Liking and Self-Competence
Scale
￿￿ ￿
Single Category Implicit Association
Task
￿￿
Economic Evaluation measures
Health care use Questionnaire ￿￿ ￿ ￿ ￿
Productivity and Disease
Questionnaire
￿￿ ￿ ￿
Work and Social Adjustment Scale ￿￿ ￿ ￿
Euroqol-6D ￿￿ ￿ ￿
Rand 36 ￿￿ ￿ ￿
Other measures ￿
Genetic information
Working Alliance Inventory ￿
Collaborative Study Psychotherapy
Rating Scale
￿￿ ￿ ***
Working Alliance Inventory-short
observer version
￿￿ ￿ ***
* Patients in the waiting list condition will receive the same baseline
assessment, they will have a second baseline assessment at 2 months follow-
up, and their 9, 14, and 26 month follow-up assessments parallel respectively
the 7, 12, and 24 month assessments of the CT and IPT group. ** The
following general predictors will be administered at baseline as well:
demographic variables, family anamnesis, childhood experiences, life-events,
reliability and expectations. *** During the treatment phase, all sessions will
be videotaped. Only a random selection of tapes will be rated.
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and behaviour vs. interpersonal functioning), approach
(directive vs. empathic-reflective) and method (home-
work assignment vs. no assignments) [27]. All sessions
will be videotaped, and a random selection of tapes will
be analysed by independent assessors on treatment
adherence (content and quality) by using the Collabora-
tive Study Psychotherapy Rating Scale - version 6
(CSPRS-6) [67], and on quality of therapeutic alliance
using the Observer version of the Working Alliance
Inventory-Short (WAI-O-S) [68-72].
Instruments
Several instruments will be used to assess the effects of
CT and IPT on depressive symptoms and other second-
ary outcomes. Furthermore, instruments will be used to
assess the mechanisms of change and the cost-effective-
ness of CT and IPT. An overview of all measurements
per assessment is given in table 1.
Clinical outcome measures
Beck Depression Inventory-II
The Beck Depression Inventory-II (BDI-II) [73,74] will
be used as the primary outcome measure of depressive
severity. The total score is the sum of the 21 items ran-
ging from 0 to 63. Higher scores reflect more severe
depressive symptoms. Several studies have shown that
the BDI-II is a strong screening measure for depression
[73-75].
Quick Inventory of Depressive Symptoms
T h eQ u i c kI n v e n t o r yo fD e p r e s s i v eS y m p t o m s( Q I D S )
[76] is a treatment sensitive measure of symptom severity
in depression. The 16 items that measure 9 criterion
domains of MDD are derived from the 30-item Inventory
of Depressive Symptomatology (IDS) [77]. The QIDS has
been shown to have highly acceptable psychometric
properties [78].
Brief Symptom Inventory
The Brief Symptom Inventory (BSI) [79] is a 53-item
self-report instrument that will be used to measure gen-
eral psychological distress. It is derived from the SCL-
90-R and several studies have demonstrated it to be an
acceptable short alternative of its longer version [80,81].
Diagnostic Inventory for Depression
The Diagnostic Inventory for Depression (DID) will be
used to assess the psychosocial impairment due to
depression, and to evaluate subjective quality of life
[82,83]. Psychometric analysis shows good reliability and
validity [82].
Longitudinal Interval Follow-up Evaluation
The modified version of the semi-structured Longitudi-
nal Interval Follow-up Evaluation (LIFE) [66] will be
used to map out the course of depressive symptoms in
the long-term follow-up phase (12-24 months). This will
be administered at the end of the follow-up (24
months). We used the MDD section of the original
interview, and added items on general functioning,
working status, relations to others and treatment- and
study experiences. The LIFE has shown to be a reliable
and valid instrument for characterizing the course of
several mental disorders examined retrospectively over
the period of one year [84,85].
Process (or mechanism) variables
Dysfunctional Attitudes
The Dysfunctional Attitude scale version a (DAS-A)
[86-88] is a self-report scale designed to measure pat-
terns of negative and absolute thinking in depressed
patients. Respondents need to report whether or not
they agree with a series of dysfunctional assumptions on
a seven point Likert-Scale. With its good internal con-
sistency and validity, it appears to be a valid measure of
dysfunctional cognitions in depressed patients [89-92].
Attributional Style
Attributional style will be measured using the Attribu-
tional Style Questionnaire (ASQ) [93,94]. In the ASQ,
participants receive 12 hypothetical events and are asked
to imagine themselves in that scenario. Subsequently
they have to decide what the major cause of the situa-
tion would be if it happened to themselves and rate the
cause along a 7-point Likert-scale on three dimensions:
Personal, Permanent and Pervasive. Depressive symp-
toms are associated with an attributional style in which
the causes of good and bad events are attributed to
internal (versus external), stable (versus unstable), and
global (versus specific) causes [95]. It is hypothesized
that if attributional style changes significantly during
therapy, the explanations of why events happen change
to external, unstable and specific. The ASQ has shown
to have good psychometric properties [93].
Implicit measure of self-esteem
A variant of the Single Category Implicit Association
Test (Sc-IAT) [96] will be administered to obtain an
implicit measure of associations with the self (self-
esteem). For the current study, we adapted the original
Sc-IAT paradigm to specifically measure feelings of
helplessness, unlovability and worthlessness, which are
considered the main themes of core beliefs in depres-
sion. The test consists of 3 blocks of trials and starts
with a practice block. In this block, positive and negative
words are presented (all words are related to the specific
core beliefs), and the task for participants is to categor-
ize these stimuli as such by pressing the appropriate key
(left or right) without making too many errors. After the
practice block, there are two test blocks. In one critical
block, stimuli representing the self (’me-trials’)s h a r ea
response key with positive stimuli, while the other key
needs to be pressed for negative stimuli. In the other
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switched. Stimuli representing the self now share a
response key with the negative stimuli. Each block is
preceded by a set of instructions concerning the dimen-
sion(s) of the categorisation task and the appropriate
key response. The rationale behind the Sc-IAT is that
the response time will be faster when two associated
concepts are mapped together on the same key, com-
pared to when two less compatible concepts are mapped
together. For example, in people with a positive sense of
self-esteem, when ‘valuable’ and ‘me’ meaning words are
mapped to the same key, the response time will be fas-
ter than for the non-compatible combination (’worthless’
and ‘me’). The Sc-IAT effect will be calculated using the
improved D-Algorithm [97]. In comparison with implicit
measures obtained via other measurement procedures,
the Sc-IAT shows good psychometric qualities [98-101].
Hopelessness
The Beck Hopelessness Scale (BHS) [102] is a self-report
instrument that determines the extent of positive and
negative beliefs about the future over the previous 7
days using 20 true-false statements. All statements are
scored 0 or 1 with the total being calculated by sum-
ming the pessimistic responses for the items. General
cut-off guidelines do not exist and it is recommended
that cut-off scores should be based upon clinical deci-
sions. The BHS has been shown to have good psycho-
metric properties for application in clinical samples
[103-105].
Interpersonal Problems
The Inventory of Interpersonal Problems (IIP) [106] is a
127-item self-report measure, which describes the types
of problems that people experience in their relationships
with others, and the level of distress associated with
them. Items are divided in two sections: participants are
asked to rate problematic behaviour that is hard for
them to do (78 items) and behaviour that they are doing
too much (49 items). The IIP provides a total score and
scores on six or eight subscales. Higher scores indicate
more interpersonal problems. Psychometric properties
of the IIP were found to be good [106].
Cognitive Reactivity
During a depressive episode, an association is formed
between depressed mood and dysfunctional thinking.
This association may remain intact even when the
depressive episode remits. The strength of this associa-
tion is called cognitive reactivity [107]. The Leiden Index
of Depression Sensitivity (LEIDS) is used to measure this
cognitive reactivity on six subscales [108]. Psychometric
qualities of this measurement are found to be good [108].
Rumination
The Ruminative Response Scale (RRS) [109,110] is a 22-
item questionnaire that will be used to detect the
responses to depressed mood that are focused on self,
symptoms, or possible consequences and causes of
mood. People are asked to indicate how often they think
about certain things on a four point Likert-scale. The
RRS shows good reliability and satisfactory validity
[109,110].
Self-Esteem
The Self Liking and Self Competence Scale Revised
(SLCS-R) [111,112] is a self-report questionnaire con-
structed to measure Self-Competence and Self-Liking,
two dimensions of self-esteem. The SLSC-R contains
eight items for each of the two dimensions. Items are
rated on a 5-point Likert scale. The subscales scores can
range from 8 to 40, with higher scores indicating higher
self-competence or higher self-liking. Psychometric
properties were found to be good [111].
Economic Evaluation
Costs
A rudimentary analysis of the cost-effectiveness of CT
and IPT will be conducted from a societal perspective.
We will distinguish three cost categories: health care
sector costs, costs for the patient and family, and pro-
ductivity cost [113]. Healthcare costs and patient and
family costs will be measured using a periodic retrospect
health care consumption questionnaire designed by de
Graaf et al. (2008) for use in the field of depression
research [114]. This questionnaire is based on an exist-
ing cost diary [115] and retrospective cost question-
naires [116,117]. Containing 52 items, it measures the
number and content of contacts with GPs, specialists,
paramedics, alternative care, psychological care, hospital
visits, medication, and self-help over a period of three
months. To measure production losses we will use the
patient modules (A-E) of the productivity and disease
questionnaire (PRODISQ) [118].
Quality of Life measures
To measure the experiential impact of the disorder, the
Work and Social Adjustment Scale (W&SAS) [119] will
be used. This 5-item self-report scale examines to what
extent the disorder impairs a person’se v e r y d a yf u n c -
tioning. Items are rated on a 9 point Likert-scale, with
higher scores indicating more severe impairment. Psy-
chometric properties of the W&SAS are found to be
good [119,120]. Furthermore, to measure generic quality
of life of the patients on the basis of societal apprecia-
tion of health condition, the EuroQol [121] will be used.
To measure quality of life in terms of impairments due
to physical and mental health status, we will use the
RAND-36 [122]. This 36 item questionnaire measures
physical and social functioning, role restriction due to
physical or emotional problems, mental health, energy,
pain, and general health perception. The RAND-36 has
s h o w nt ob ear e l i a b l e ,v a l i da n ds e n s i t i v em e a s u r e
[122].
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Working Alliance
The past decades, it has become clear that therapeutic
alliance is an essential element of the therapeutic pro-
cess [123]. The stronger the collaborative and affective
bond between patient and therapist, the larger the thera-
peutic change [124]. To measure this bond, the Working
Alliance Inventory (WAI) [69,125] will be used. The
questionnaire consists of 36 items rated on a 5-point
Likert scale and will be filled out by both patient and
therapist. The internal consistency of this instrument
was found to be high. As has been mentioned earlier, all
therapy sessions will be videotaped. Therapeutic alliance
will also be assessed by rating a random selection of
videotapes using the Observer version of the Working
Alliance Inventory-Short (WAI-O-S) [71,72].
Genetics
T h e r ei se v i d e n c et h a tt h es a m eg e n e t i cf a c t o r st h a t
appear to moderate the efficacy of different classes of
antidepressants are also involved in aspects of cognitive
functioning [126]. The same polymorphisms are also
associated with reactions on aversive stimuli [127-129].
Because changes in regulation of emotions and cognitive
processes are core elements in therapeutic approaches
such as CT and IPT, we expect that the efficacy of these
therapies is influenced by genetic variations in poly-
morphisms. Therefore, we will obtain genetic material at
baseline (buccal cotton swabs).
Analyses
Data-analysis will include intention-to-treat analyses,
per-protocol analyses, change analyses and prognostic
analyses. Analyses will include elementary head-to-head
comparisons of the interventi o ng r o u p sa sw e l la sm o r e
complicated multivariate analyses (e.g., individual time
series analysis, logistic regression analysis, multilevel ana-
lyses). Furthermore, in ancillary analysis, subgroups of
the study sample according to symptom severity and
DSM-IV classification will be examined for differential
effects. In addition, we will determine the proportion of
patients that show reliable and clinically significant
improvement on the outcome measures. Our calculations
will be based on the method of Jacobson and Truax [130]
which prescribes that Clinical Improvement (CI) is based
on both Reliable Change (RC), the extent to which the
pre-to-post-difference score is reliable; and on Clinical
Significant change (CSC), the extent to which post-treat-
ment scores are clinically meaningful [131]. We will use
chi-square tests to test the frequency differences in the
RC, CSC, and CI between the three intervention groups.
R e l a p s e( e p i s o d eo fM D Da f t e rr e m i s s i o n )a n dr e c u r -
rence (episode of MDD after recovery) in the course of
follow-up (12 and 24 months) will be assessed using
survival analysis (Cox proportional hazards regression).
Furthermore, using multi-level mediation models, we
will investigate various potential treatment mediators
(psychological processes responsible for therapeutic
change) to identify mechanisms of change. We will use
the revised and expanded McArthur guidelines with a
central focus on the temporal aspect [40,41]. Further-
more, we will use structural equation modelling to test
the relative strength of the factors involved (path analy-
sis), an approach already successfully applied by Oei and
colleagues [48].
Discussion
We presented the protocol of a study assessing the
effectiveness, mechanisms of change and prevention of
relapse/recurrence of CT and IPT for depression. While
it is well known that both CT and IPT are effective
treatments for depression, it is not entirely clear yet
whether one therapy is superior to the other, especially
in the long term. Furthermore, since response rates of
both therapies are insufficient and the risk of relapse
and recurrence is high, the challenge in contemporary
depression research is the improvement of treatments to
increase response rates and prevent relapse and recur-
rence. Studying the mechanisms of change in treatment
might be a first step in improving every day clinical
practice. Although in the past decades attention for
mechanisms of change in psychotherapy has grown, this
type of research is still in its infancy. It may be clear
that there is a need for renewed methodologically well-
considered research. With the current study, we hope to
provide new insights in the issues stated above.
Methodological Considerations
The current study has several strengths, including ran-
domisation of patients to three conditions (CT, IPT and
a waiting list condition). The used design (RCT) is not
only the standard for the evaluation of effectiveness of
psychiatric treatments, but is also very valuable in study-
ing mechanisms of therapeutic change [132,133].
Furthermore, we follow the recommendation of Kazdin
to measure multiple potential mediators simultaneously
and to include multiple follow-up measures at various
time-points throughout a 2-year follow-up period. We
assess both mediators and outcomes before and after
therapy. This repeated measures design will provide a
unique opportunity to evaluate whether change in cog-
nitions occurs in advance of, and is related to, reduction
in symptoms. In addition, to our knowledge, we are the
first to compare CT with IPT head-to-head for relapse
prevention and assess the underlying mechanisms of
change using both explicit and implicit measures in a
treatment study of depression to examine the level of
therapeutic changes. To conclude, we will use state-of-
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causality and mechanisms of change.
However, the current study also has a number of limita-
tions. In spite of the fact that we consider many potential
mechanisms, there probably will be important (latent) pro-
cesses that are not assessed in the current study. Even
though we will use analysing techniques to prevent these
biases as much as possible, there still is a chance that
results will be contributed to the measured variables,
whereas they are actually caused by other latent variables.
Conclusions
The current study will compare CT and IPT head-to-head
in terms of effectiveness and the prevention of relapse.
Furthermore, in order to investigate mechanisms of
change, we will investigate potential mediators of CT for
depression and test their specificity in comparison to IPT
and vice versa. By including assessments on multiple time
points in both the treatment- and follow-up phase, we try
to investigate temporal relationships between change in
potential mediators and outcome measures that are
needed to identify causal pathways of therapeutic change.
We will assess both specific and common treatment fac-
tors using both explicit and implicit measures. We hope to
provide new insights in the mechanisms of change of CT
and IPT for depression and through here contribute to the
improvement of health care for adults suffering from
depression.
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